Serotypes, antimicrobial resistance and genotypes of Streptococcus pneumoniae associated with infections in cancer patients in Brazil

Cardoso, Nayara Torres; Santos, Bárbara Araújo dos; Barbosa, André Victor; Superti, Silvana; Teixeira, Lúcia Martins; Neves, Felipe Piedade Gonçalves

doi:10.1016/j.diagmicrobio.2016.11.017

Cited by 10 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PCV-10, PCV-13, and PPSV-23 had an estimated coverage of capsular types of 34%, 50% and 68%, respectively. 30 Considering that vaccine effectiveness in patients with cancer is lower than in the general population, an improved vaccine that covers more serotypes is needed.…”

Section: Discussionmentioning

confidence: 99%

Invasive pneumococcal disease in children with cancer: Incidence density, risk factors and isolated serotypes

Lages

Carlesse

Boettger

et al. 2020

The Brazilian Journal of Infectious Diseases

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Invasive pneumococcal disease in children with cancer: Incidence density, risk factors and isolated serotypes

Lages

Carlesse

Boettger

et al. 2020

The Brazilian Journal of Infectious Diseases

View full text Add to dashboard Cite

“…Of these, 3, 9 N and 6A are highly virulent, along with serotypes 19F and 6B. In particular, serotype 3 is described as being strongly encapsulated when compared to other serotypes 24,25 , which gives it a high virulence. In addition, types 19A and 23F have a high relative risk previously reported 24 .…”

Section: Discussionmentioning

confidence: 99%

“…In previous multi-center studies 21,31 , there was a higher mortality rate from IPDs in general in Brazil and Latin America compared to other countries, which may explain, in part, the high mortality in this study. In addition, other factors possibly implicated would be infection with highly virulent serotypes 23,24 , especially serotype 3, the higher incidence of polymicrobial bacteremia, and the high incidence of neutropenia 12 .…”

Section: Discussionmentioning

confidence: 99%

Fluoroquinolone treatment as a protective factor for 10-day mortality in Streptococcus pneumoniae bacteremia in cancer patients

Fontana

Ibrahim

Bonazzi

et al. 2021

Sci Rep

View full text Add to dashboard Cite

To evaluate the prognostic factors in adult cancer patients with pneumococcal bacteremia, describe episode features and the phenotypic characteristics of the isolated strains. We evaluated the episodes in patients admitted to a cancer hospital between 2009 and 2015. The outcomes were defined as 48 h mortality and mortality within 10 days after the episode. The variables evaluated were: age, sex, ethnicity, ECOG, Karnofsky score, SOFA, cancer type, metastasis, chemotherapy, radiotherapy, neutropenia, previous antibiotic therapy, community or healthcare-acquired infection, comorbidities, smoking, pneumococcal vaccination, infection site, presence of fever, polymicrobial infection, antimicrobial susceptibility, serotype and treatment. 165 episodes were detected in 161 patients. The mean age was 61.3 years; solid tumors were the most prevalent (75%). 48 h and 10-day mortality were 21% (34/161) and 43% (70/161) respectively. The 48 h mortality- associated risk factors were SOFA and polymicrobial bacteremia; 10-day mortality-associated risk factors were fever, neutropenia, ECOG 3/4, SOFA and fluoroquinolones as a protective factor. Pneumococcal bacteremia presented high mortality in cancer patients, with prognosis related to intrinsic host factors and infection episodes features. Fluoroquinolone treatment, a protective factor in 10-day mortality, has potential use for IPDs and severe community-acquired pneumonia in cancer patients.

show abstract

“…(26) Solid tumors and hematological malignancies also predispose individuals to infections, especially by gram-positive bacteria. (27) In the studied population, immunosuppression was more prevalent in the elderly (p = 0.02).…”

Section: Discussionmentioning

confidence: 84%

Mortalidade e custos da pneumonia pneumocócica em adultos: um estudo transversal

et al. 2019

View full text Add to dashboard Cite

RESUMO Objetivo A pneumonia pneumocócica é uma causa significativa de morbimortalidade entre adultos. Desta maneira, o objetivo principal deste estudo foi avaliar a mortalidade intra-hospitalar e os custos relacionados à doença adquirida em adultos. Métodos Este estudo transversal utilizou prontuários de pacientes adultos com pneumonia pneumocócica internados em um hospital universitário no Brasil, de outubro de 2009 a abril de 2017. Todos os pacientes com idade ≥ 18 anos e diagnosticados com pneumonia pneumocócica foram incluídos. Dados como os fatores de risco, a internação em unidade de terapia intensiva, o tempo de internação, a mortalidade hospitalar e os custos diretos e indiretos foram analisados. Resultados No total, 186 pacientes foram selecionados. A taxa média de mortalidade intra-hospitalar foi de 18% para adultos com idade < 65 anos e 23% para os idosos (≥ 65 anos). A pneumonia pneumocócica bacterêmica acometeu 20% dos pacientes em ambos os grupos, principalmente por doença respiratória crônica (OR ajustada: 3,07; IC95%: 1,23‐7,65; p < 0,01). Após levantamento das internações ocorridas no período de sete anos de tratamento, verificou-se que os custos diretos e indiretos totais anuais foram de US$ 28.188 para adultos < 65 anos (US$ 1.746 per capita) e US$ 16.350 para os idosos (US$ 2.119 per capita). Conclusão A pneumonia pneumocócica continua sendo uma importante causa de morbimortalidade entre adultos, afetando significativamente os custos diretos e indiretos. Esses resultados sugerem a necessidade de estratégias de prevenção para todos os adultos, especialmente para pacientes com doenças respiratórias crônicas.

show abstract

Serotypes, antimicrobial resistance and genotypes of Streptococcus pneumoniae associated with infections in cancer patients in Brazil

Cited by 10 publications

References 23 publications

Invasive pneumococcal disease in children with cancer: Incidence density, risk factors and isolated serotypes

Invasive pneumococcal disease in children with cancer: Incidence density, risk factors and isolated serotypes

Fluoroquinolone treatment as a protective factor for 10-day mortality in Streptococcus pneumoniae bacteremia in cancer patients

Mortalidade e custos da pneumonia pneumocócica em adultos: um estudo transversal

Contact Info

Product

Resources

About